Becton Dickinson & Co (MIL:1BDX)
€ 211.5 -2.1 (-0.98%) Market Cap: 60.75 Bil Enterprise Value: 77.74 Bil PE Ratio: 37.37 PB Ratio: 2.48 GF Score: 64/100

Becton Dickinson and Co at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 03:30PM GMT
Release Date Price: €216.5
Robert Justin Marcus
JPMorgan Chase & Co, Research Division - Analyst

Good morning, everyone. I'm Robbie Marcus, med tech analyst at JPMorgan. Really happy to kick off day 2 of the Healthcare Conference. We're starting off with a presentation by Becton, Dickinson. I'd like to introduce Tom Polen, the CEO, do a quick presentation, then I'll join on with some others from the company for some Q&A.

Tom?

Thomas E. Polen
Becton, Dickinson and Company - President, CEO & Chairman

Okay. Thank you, Robbie. Okay. Good morning, everyone. And again, thank you, Robbie. We appreciate everyone's interest in BD. I'm pleased to update you today on the strong progress we have made advancing our BD 2025 strategic goals. This includes consistently exceeding our durable 5.5% revenue growth profile and driving 3-year base organic revenue growth of nearly 7%, inclusive of our FY '24 guidance. This has been achieved by systematically shifting our portfolio into higher growth spaces, both organically through CapEx and R&D, and inorganically through M&A

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot